ENTRY       D11894                      Drug
NAME        Amivantamab (USAN/INN);
            Amivantamab (genetical recombination) (JAN);
            Amivantamab-vmjw;
            Rybrevant (TN)
PRODUCT     RYBREVANT (Janssen Biotech)
FORMULA     C6472H10014N1730O2023S46
EXACT_MASS  145810.1054
MOL_WEIGHT  145900.1288
SEQUENCE    (A chain)
            QVQLVESGGG VVQPGRSLRL SCAASGFTFS TYGMHWVRQA PGKGLEWVAV IWDDGSYKYY
            GDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDG ITMVRGVMKD YFDYWGQGTL
            VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
            VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KRVEPKSCDK THTCPPCPAP
            ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
            EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP
            PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFLLYSKLTV
            DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
            (B chain)
            QVQLVQSGAE VKKPGASVKV SCETSGYTFT SYGISWVRQA PGHGLEWMGW ISAYNGYTNY
            AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDL RGTNYFDYWG QGTLVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ
            QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
            (C chain)
            AIQLTQSPSS LSASVGDRVT ITCRASQDIS SALVWYQQKP GKAPKLLIYD ASSLESGVPS
            RFSGSESGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (D chain)
            DIQMTQSPSS VSASVGDRVT ITCRASQGIS NWLAWFQHKP GKAPKLLIYA ASSLLSGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ANSFPITFGQ GTRLEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: A22-A96, A152-A208, A228-C214, A234-B228, A237-B231, A269-A329, A375-A433, B22-B96, B146-B202, B222-D214, B263-B323, B369-B427, C23-C88, C134-C194, D23-D88, D134-D194)
  TYPE      Peptide
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03162  EGFR inhibitor
REMARK      ATC code: L01FX18
            Product: D11894<US>
EFFICACY    Antineoplastic
  DISEASE   Non-small cell lung cancer (EGFR exon 20 insertion) [DS:H00014]
  TYPE      Monoclonal antibody, bispecific antibody
TARGET      EGFR* [HSA_VAR:1956v2] [HSA:1956] [KO:K04361]
            EGFR [HSA:1956] [KO:K04361]
            MET [HSA:4233] [KO:K05099]
  PATHWAY   hsa04010(1956+1956+4233)  MAPK signaling pathway
            hsa04014(1956+1956+4233)  Ras signaling pathway
            hsa04015(1956+1956+4233)  Rap1 signaling pathway
            hsa04151(1956+1956+4233)  PI3K-Akt signaling pathway
            hsa04510(1956+1956+4233)  Focal adhesion
            hsa04520(1956+1956+4233)  Adherens junction
            hsa05200(1956+1956+4233)  Pathways in cancer
            hsa05223(1956+1956+4233)  Non-small cell lung cancer
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX18 Amivantamab
                  D11894  Amivantamab (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Amivantamab
                D11894  Amivantamab (USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03162  EGFR inhibitor
                 D11894  Amivantamab
            Drug classes [BR:br08332]
             Antineoplastic
              DG03162  EGFR inhibitor
               D11894  Amivantamab
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               EGFR family
                EGFR
                 D11894  Amivantamab (USAN/INN) &lt;US&gt;
                EGFR* [HSA_VAR:1956v2]
                 D11894  Amivantamab (USAN/INN) &lt;US&gt;
               MET family
                MET
                 D11894  Amivantamab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11894
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11894
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D11894
DBLINKS     CAS: 2171511-58-1
///
